ADELAIDE, Australia / RankWire.AI / – Researchers from Adelaide University and the Olivia Newton-John Cancer Research Institute have pinpointed a novel molecular switch that promotes the dissemination of highly aggressive tumors. Their findings, published in EMBO Molecular Medicine, highlight an innovative approach to addressing triple-negative breast cancer by re-establishing a crucial regulatory molecule called miR-342. This breakthrough paves the way for new strategies to prevent life-threatening secondary cancers in organs such as the lungs and bones.
In Australia, triple-negative breast cancer makes up about 10% to 15% of the roughly 21,000 new breast cancer cases diagnosed each year but accounts for a larger share of mortality. This subtype is characterized by the absence of estrogen, progesterone, and HER2 receptors, which makes targeted hormone therapies ineffective. The lead researchers showed that when levels of miR-342 decrease, a cancer-promoting pathway known as E2F becomes hyperactive, enabling dormant cancer cells to migrate and establish dangerous secondary tumors across the body.
Potential for Diagnostic Biomarker Screening to Identify Patients Who Might Benefit Most
Using pre-clinical models, scientists demonstrated that boosting miR-342 levels substantially decreased the ability of cancer cells to metastasize to distant sites. They also found that palbociclib, an existing CDK4/6 inhibitor drug approved for hormone receptor-positive breast cancers, significantly slowed metastatic tumor growth in models with low miR-342 expression. These results suggest that assessing miR-342 levels could help clinicians repurpose current drugs to better treat patients at high risk of metastasis.
Associate Professor Philip Gregory from Adelaide University’s Centre for Cancer Biology, a co-senior author, emphasized that stopping metastasis continues to be the main obstacle in treating aggressive breast cancers. Gregory explained that because palbociclib targets the overactive E2F pathway, administering it after cancer cells have spread can prevent tiny deposits from enlarging. This approach shifts the focus from merely shrinking primary tumors to halting the development of microscopic secondary cancers that can threaten life.
miR-342 as a Central Regulator of Key Cancer Genes
The research team pointed out that triple-negative breast cancer exhibits significant biological diversity, which has historically made the development of broad-spectrum targeted treatments difficult. By identifying a specific molecular vulnerability common to a particular patient subgroup, this study offers the potential for personalized therapy options. As Australian scientists continue to explore this promising new method for fighting triple-negative breast cancer, efforts are underway to validate the findings using patient-derived models prior to initiating clinical trials.
Cancer specialists and research organizations across Australia expressed enthusiasm about the breakthrough, emphasizing the critical need to expand treatment options when conventional therapies fail. The research team is also planning to work with international clinical networks to speed up biomarker screening initiatives. Confirming the utility of miR-342 testing could soon enable healthcare providers to better identify suitable candidates for targeted CDK4/6 inhibitor therapies during early intervention stages.